Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 4 1Phase 3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 2Multiple Myeloma 2Lymphoma 2Head and Neck Neoplasms 2Stomatitis 1Myelodysplastic Syndromes 1Mucositis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Fibroblast Growth Factor 7 × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT03100877 2017-12-13

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡